Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806035 | 0.80 | KDR (1.00) | KDRALDH1A1MEN1KMT2A | |
| SCHEMBL788175 | 0.77 | KDR (0.78) | KDRALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL1396133 | 0.77 | NPSR1 (0.57) | KDRMAPK1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL31359827 | 0.77 | NPSR1 (0.57) | KDRMAPK1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL15077148 | 0.76 | KDR (0.81) | KDRALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL7904780 | 0.75 | ALDH1A1 (0.60) | MAPK1ALDH1A1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL31359722 | 0.74 | KMT2A (0.57) | KDRALDH1A1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL1396090 | 0.74 | KMT2A (0.57) | KDRALDH1A1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL580414 | 0.74 | MAPT (0.49) | MAPK1ALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL29537275 | 0.74 | MAPT (0.49) | MAPK1ALDH1A1HPGDSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616443-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | KDR 1782/4885MAPK1 51/4885ALDH1A1 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.